Cryo-Cell International Inc.
CCELCryo-Cell International Inc. is a biotechnology company specializing in cord blood and tissue banking services. Founded in 1989, it provides families with the option to store stem cell-rich cord blood and tissue for potential future medical treatments. The company operates internationally, offering processing, storage, and preservation of cord blood units for use in regenerative medicine and hematopoietic stem cell transplants.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 30, 2025 | $0.15 | 2025-05-21 | 2025-05-21 |
| February 28, 2025 | $0.25 | 2025-02-14 | 2025-02-14 |
| November 29, 2024 | $0.25 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Consistent Payer: Cryo-Cell International Inc. has rewarded shareholders with 3 dividend payments over the past 1 years.
- Total Returned Value: Investors who held CCEL shares during this period received a total of $0.65 per share in dividend income.
- Latest Payout: The most recent dividend of $0.15/share was paid 414 days ago, on May 30, 2025.
- Yield & Schedule: CCEL currently pays dividends quarterly with an annual yield of 18.79%.
- Dividend Growth: Since 2024, the dividend payout has decreased by 40.0%, from $0.25 to $0.15.
Company News
The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North Ame...
The global stem cell banking market is projected to reach $18.65 billion by 2031, growing at a CAGR of 18.30% due to advancements in cryopreservation, cell bank preparation, and the rising adoption of stem cell therapy. The market is driven by increased awareness of stem cell therapy, growing healthcare investments, and trends in personalized med...
The global stem cell banking market is expected to reach a value of USD 18.65 Billion by 2031, growing at a CAGR of 18.30% during the forecast period. The market is driven by advancements in cryopreservation, increased application of stem cell treatments, and the trend of late parenting leading to interest in cord blood banking.
OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022.
OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022.
